EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›ARDX

ARDX

ARDELYX, INC.

Next earnings Aug 3, 2026 · consensus $-0.04 EPS, $129M rev

Last earnings +5.3% on 2026-04-30

Sell
$5.55
▼ -8.42%
$5.55▲ +52.89%
over 1Y
L $3.63EODHDH $7.99
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-8.4%
1W-12.9%
1M-10.0%
3M+1.3%
YTD-9.8%
1Y+52.9%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Sell
Quality
D
Valuation
Fair value
Filings
Watch
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 17 analysts
Strong Buy

Revenue grew 22.1% YoY; but unprofitable (net margin -15.1%).

Revenue (FY2025) $407M · FY2025

ARDELYX, INC. shows $407M in FY2025 revenue (+22.1% YoY), a -15.1% net margin, and -36.9% ROE.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$10.1M$52.2M$124M$334M$407M
Gross profit—————
Operating income-$154M-$63.8M-$63.3M-$27.9M-$41.0M
Net income-$158M-$67.2M-$66.1M-$39.1M-$61.6M
Diluted EPS-$1.52-$0.42-$0.30-$0.17-$0.26
Net margin-1566.5%-128.9%-53.1%-11.7%-15.1%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$1.50B
EV / EBITDA—
EV / Sales3.7
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-4.5%
FCF yield-3.2%

Quality & risk

ROIC (est.)-8.8%
Free cash flow-$44.0M
Total debt$203M
Net cash-$135M
Altman Z-Score1.04 distress
Piotroski F-Score3/9

Capital returns

Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+2.9%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 8-K Officer / director change2026-06-17
  2. 8-K Earnings results2026-04-30
  3. 10-Q Quarterly report2026-04-30
  4. DEF 14A Proxy statement2026-04-29
  5. 8-K Earnings results2026-02-19
  6. 10-K Annual report2026-02-19
  7. 8-K Earnings results2026-01-08
  8. 8-K Officer / director change2025-12-17
  9. 8-K Earnings results2025-10-30

Recent filings

all on EDGAR ↗
4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-162026-06-18open ↗144Filing2026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗4Period ending 2026-06-162026-06-18open ↗8-KPeriod ending 2026-06-162026-06-17open ↗4Period ending 2026-06-152026-06-17open ↗144/AFiling2026-06-17open ↗

Quality score

D
ValueGrowthProfitHealthMom.
ValueB
GrowthC-
ProfitabilityF
Financial healthC
Momentum—
  • ✓Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✗Liabilities below 2× equity
Revenue
$407M
+22.1% YoY
Net margin
-15.1%
ROE
-36.9%
P/E
—

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$407M+22.1%
Net income-$61.6M-57.4%
Gross profit$4.68M+118.6%
Operating income-$41.0M-46.6%
Diluted EPS-$0.26-52.9%
Cash & equivalents$68.0M+4.7%
Total assets$502M+15.1%
Total liabilities$335M+27.5%
Stockholders' equity$167M-3.7%
Gross: 1.1%Op.: -10.1%L/E: 2.00x

Frequently asked

Is ARDELYX, INC. (ARDX) a buy?
ARDX currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 22.1% YoY; but unprofitable (net margin -15.1%).
What is ARDELYX, INC.'s quality score?
ARDX scores 48.09803921568627/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001437402, latest 10-Q filed 2026-04-30) · EODHD · as of 6/26/2026, 6:04:08 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 0 open-market buys · 1 sale

2026-06-18
Williams Laura A
Chief Patient Officer
Exercise31.0K @ $0.99$30.7K
2026-06-18
Williams Laura A
Chief Patient Officer
Sell81.9K @ $5.99$490K
2026-06-16
Parsey Merdad
Director
Award26.5K
2026-06-16
Rodgers Richard J
Director
Award26.5K
2026-06-16
MOTT DAVID M
Director
Award20.3K
2026-06-16
MOTT DAVID M
Director
Award26.5K
2026-06-16
Cadoret-Manier Onaiza
Director
Award26.5K
2026-06-16
Bhanji Muna
Director
Award26.5K
2026-06-16
Bertrand William C JR
Director
Award12.3K
2026-06-16
Bertrand William C JR
Director
Award26.5K
2026-06-16
Bazemore Robert B
Director
Award26.5K

Earnings history

beat/miss · move
2026-04-30Miss -1.4% est▲ +5.32%8-K ↗
2026-02-19Miss -100.0% est▲ +0.30%8-K ↗
2026-01-08Miss -100.0% est▲ +20.07%8-K ↗
2025-10-30Beat +100.0% est▲ +1.01%8-K ↗
2025-08-04Beat +41.3% est▲ +1.39%8-K ↗
2025-05-01—▼ -0.64%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
Ardelyx stock decline attributed to setback in Xphozah appealBearish
seekingalpha.com· 2026-06-26
What’s Fueling Optimism Around Ardelyx, Inc. (ARDX)’s Sales and Pipeline?Bullish
finance.yahoo.com· 2026-06-23
Should You Buy Ardelyx (ARDX)?Bullish
finance.yahoo.com· 2026-05-30
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical MeetingsBullish
globenewswire.com· 2026-05-07
Ardelyx reiterates 2026 guidance as IBSRELA targets $1B in 2029 while advancing ACCEL CIC Phase III enrollment by year-endBullish
seekingalpha.com· 2026-05-01
Ardelyx, Inc. Q1 2026 Earnings Call SummaryBullish
finance.yahoo.com· 2026-05-01

Vs tracked universe

compare →

1044 tracked peers · median

EDGAR Score48 vs 67
Revenue growth22.1% vs 7.1%
Net margin-15.1% vs 10.5%
Return on equity-36.9% vs 12.3%
P/E— vs 25.5

News sentiment

EODHD · 6d
Bearish
-0.22
vs typical · 8 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.